ישראל - עברית - Ministry of Health

unipharm ltd, israel - clopidogrel as hydrogen sulfate - טבליה - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : patients suffering from myocardial infarction (from a few days until less than 35 days ) ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ) in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg . clo

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate - טבליות מצופות פילם - clopidogrel as besylate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - tirofiban as hydrochloride monohydrate - תמיסה לאינפוזיה - tirofiban as hydrochloride monohydrate 0.05 mg/ml - tirofiban - tirofiban - aggrastat in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy. in this setting, aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - tirofiban as hydrochloride monohydrate 0.25 mg/ml - solution for infusion - tirofiban - aggrastat in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy. in this setting, aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - ramipril 2.5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - ramipril 5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - ramipril - קפסולות - ramipril 10 mg - ramipril - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 10 mg - ramipril - ramipril - hypertension . congestive heart failure . reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.